With the new agreement, BioDiem gains exclusive license to the technology which, although in development for hepatitis, may also have applicability in a range of other diseases.
As a part of the agreement, BioDiem established a collaborative research program with the University of Canberra to further advance the technology.
BioDiem CEO Julie Phillips said the company established an important research partnership with the University of Canberra and its world-leading researchers.
"This technology is built on excellent science and the potential applications in hepatitis are very exciting," Phillips added.
Research supports the technology’s use in the development of vaccines for hepatitis including hepatitis B and D, according to the company.